NCT05747157View on ClinicalTrials.gov

Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

February 15, 2023

Primary Completion Date

February 1, 2025

Study Completion Date

May 15, 2025

Conditions
B-cell Acute Lymphoblastic Leukemia
Interventions
DRUG

Metabolically Armed CD19 CAR-T cells

Each subject receive metabolically armed CD19 CAR-T cells by intravenous infusion.

Trial Locations (1)

Unknown

RECRUITING

Anhui Provincial Hospital, Hefei

Sponsors

Collaborators (1)

Leman Biotech Co., Ltd.
All Listed Sponsors
collaborator

Leman Biotech Co., Ltd.

INDUSTRY

lead

Anhui Provincial Hospital

OTHER_GOV